CT-KIBRA–mediated synapse repair could be a valuable approach in combination with pathology-modifying strategies designed to slow progression of cognitive decline by reducing tau levels or clearing toxic forms of tau from the brain, which are being tested in ongoing clinical trials (73, 74). The gene discussed is MAPT; the disease is Mental deterioration.